Pursuant to Regulation 30 read with read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘Listing Regulations’), OneSource Specialty Pharma has informed that SES ESG Research (SES ESG) has assigned an Environmental, Social, and Governance (ESG) score of 65.7 vide its report received by the Company on 11th February 2026, based on FY 2024-25 data available in the public domain. The Company had not engaged SES for the ESG Rating. SES has independently prepared the report based on data pertaining to the Company available in public domain. This intimation is in accordance with the SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: